I meccanismi patogenetici alla base del processo di calcificazione vascolare in corso di insufficienza renale

Ganesh S.K. , Stack A.G. , Levin N.W. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131–8.

Block G.A. , Hulbert-Shearon T.E. , Levin N.W. , Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17.

European Transplantation and Dialysis Association. Report on Management of Renal Failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10(suppl 5): S12.

US Renal Data System: Causes of death. Annual Data Report. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 1995; 14: 79–90.

Goodman W.G. , Goldin J. , Kuizon B.D. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. NEJM 2000; 342: 1478–83.

London G.M. , Pannier B. , Marchais S.J. , Guerin A.P. Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000; 11: 778–83.

Jakoby M.G. IV , and Semenkovich C.F. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens 2000; 9: 11–5.

Cozzolino M. , Dusso A. , Slatopolsky E. Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001; 12: 2511–6.

Jono S. , McKee M.D. , Murry C.E. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10–7.

Giachelli C.M. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14(suppl): S300–4.

Ducy P. , Zhang R. , Geoffroy V. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747–54.

Kuro-o M. , Matsumura Y. , Aizawa H. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390(6655): 45–51.

Christian R.C. , Fitzpatrick L.A. Vascular calcification. Curr Opin Nephrol Hypertens 1999; 8: 443–8.

Cozzolino M. , Brancaccio D. , Gallieni M. , and E. Slatopolsky. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429–36.

Schinke T. , Amendt C. , Trindl A. The serum protein 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996; 271: 20789–96.

Schafer C. , Heiss A. , Schwarz A. The serum protein 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357–66.

Ketteler M. , Bongartz P. , Westenfeld R. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827–33.

Cozzolino M. , Galassi A , Biondi ML Serum Fetuin-A Levels as a Link between Inflammation and Cardiovascular Calcification in Haemodialysis Patients. Am J Nephrol 2006; 26: 423–9.

Cozzolino M. , Galassi A. , Biondi M.L. Decreased serum fetuin-A levels after a single haemodialysis session. Nephrol Dial Transplant 2007; 22: 290–1.

Luo G. , Ducy P. , McKee M.D. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78–81.

Shearer M.J. Role of vitamin K and gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 2000; 3: 433–8.

Jono S. , Ikari Y. , Vermeer C. Matrix Gla protein is associated with coronary artery calcification assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790–4.

Hermann S-M , Whatling C. , Brand E. Polymorphisms of the human matrix Gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2386–93.

Brancaccio D. , Biondi M.L. , Gallieni M. Matrix gla protein gene polymorphisms and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005; 25: 548–552.

Bucay N. , Sarosi I. , Dunstan C.R. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260–8.

Emery J.G. , McDonnell P. , Burke M.B. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363–7.

Shoppet M. , AL-Fakhri N. , Franke F.E. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104–12.

Jono S. , Ikari Y. , Shioi A. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192–4.

Kiechl S. , Schett G. , Wenning G. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175–80.

Nitta K. , Akiba T. , Uccida K. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42: 303–9.

Mazzaferro S. , Pasquali M. , Pugliese F. Serum Levels of Calcification Inhibition Proteins and Coronary Artery Calcium Score: Comparison Between Transplantation and Dialysis. Am J Nephrol 2007 (in press).

Morena M. , Terrier N. , Jaussent I. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006; 17: 262–70.

Hjelemsaeth J. , Ueland T. , Flyvbierg A. Early post-transplant serum osteoprotegerin levels predict long-term (8 year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006; 17: 1746–54.

Haas M. , Leko-Mohr Z. , Roschger P. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002; 39: 580–6.

Coen G. , Ballanti P. , Balducci A. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233–8.

Kazama J.J. , Shigematsu T. , Yano K. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39: 525–32.

Kudlacek S. , Schneider B. , Woloszczuk W. , Pietschmann P. , Willvonseder R. Serum levels of osteoprotegerin in-crease with age in a healthy adult population. Bone 2003; 32: 681–6.

Moe S.M. , Reslerova M. , Ketteler M. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295–304.

Lund R.J. , Davies M.R. , Hruska K. Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens 2002; 11: 31–6.

Davies M.R. , Lund R.J. , Hruska K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003; 14: 1559–67.

Li T , Surendran K. , Zawaideh M.A. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens 2004, 13: 417–22.

Luo G. , Hofmann C. , Bronckers A.L. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 1995; 9: 2808–20.

Wang S. , Chen Q. , Simon T.C. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037–49.

Dorai H. , Vukicevic S. , Sampath T.K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000; 184: 37–45.

Lund R.J. , Davies M.R. , Brown A.J. , Hruska K.A. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004; 15: 359–69.